<?xml version="1.0" encoding="utf-8" ?>

<article article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher-id">TOBIOJ</journal-id>
            <journal-title>The Open Biology Journal</journal-title>
            <abbrev-journal-title abbrev-type="pubmed">Open Bio. J.</abbrev-journal-title>
            <issn pub-type="epub">1874-1967</issn>
            <publisher>
                <publisher-name>Bentham Open</publisher-name>
            </publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">TOBIOJ-2-222</article-id>
            <article-id pub-id-type="doi">10.2174/1874196700902010222</article-id>
            <article-categories>
                <subj-group subj-group-type="heading">
                    <subject>Biology</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Amyloid Oligomer Structures and Toxicity</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                    <name>
                        <surname>G. Glabe</surname>
                        <given-names>Charles</given-names>
                    </name>
                    <xref ref-type="corresp" rid="cor1">&#x002A;</xref>
                </contrib>
                <aff>Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697, USA</aff>
            </contrib-group>
            <author-notes>
                <corresp id="cor1">
                    <label>&#x002A;</label>Address correspondence to this author at the Department of Molecular
Biology and Biochemistry, University of California, Irvine, California
92697, USA; Fax: +1 949 824 8551; E-mail: <email xlink:href="cglabe@uci.edu">cglabe@uci.edu</email></corresp>
            </author-notes>
            <pub-date pub-type="epub">
                <day>31</day>
                <month>12</month>
                <year>2009</year>
            </pub-date>
            <pub-date pub-type="collection">
                <year>2009</year>
            </pub-date>
            <volume>2</volume>
            <fpage>222</fpage>
            <lpage>227</lpage>
            <history>
                <date date-type="received">
                    <day>30</day>
                    <month>04</month>
                    <year>2009</year>
                </date>
                <date date-type="rev-recd">
                    <day>03</day>
                    <month>07</month>
                    <year>2009</year>
                </date>
                <date date-type="accepted">
                    <day>07</day>
                    <month>08</month>
                    <year>2009</year>
                </date>
            </history>
            <permissions>
                <copyright-statement>&#x00A9; 2009 Charles G. Glabe</copyright-statement>
                <copyright-year>2009</copyright-year>
                <copyright-holder>Charles G. Glabe</copyright-holder>
                <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/legalcode">
                    <p>This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/legalcode">https://creativecommons.org/licenses/by/4.0/legalcode</uri>). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p>
                </license>
            </permissions>
            <abstract>
                <p>Amyloid accumulation is commonly associated with a number of important human degenerative diseases and
recent findings indicate that soluble amyloid oligomers may represent the primary pathological species in degenerative
diseases. Amyloid oligomers are structurally and morphologically diverse, raising the question on whether this diversity is
pathologically significant and whether different types of oligomers may have different toxic activities. Many of the
amyloids associated with neurodegenerative diseases form three immunologically distinct types of oligomers. Fibrillar
oligomers are structurally related to fibrils and may represent small pieces of fibrils or fibril protofilaments. Prefibrillar
oligomers are kinetic intermediates in fibril formation and annular protofibrils that resemble membrane pores. These three
classes of oligomers share common structures and toxic activities. Focus on these common mechanisms of toxicity
provides a means of simplifying the list of primary disease mechanisms and opens the possibility of developing broad
spectrum therapeutics that target several amyloid related degenerative diseases.</p>
            </abstract>
            <kwd-group>
                <title>Keywords</title>
                <kwd>Amyloid</kwd>
                <kwd>structure</kwd>
                <kwd>toxicity</kwd>
                <kwd>amyloid oligomers</kwd>
                <kwd>amyloid disease</kwd>
                <kwd>pathogenesis</kwd>
            </kwd-group>
        </article-meta>
    </front>
</article>
